Dr. Nicole Grieselhuber on Advancing Treatment for High-Risk MDS
By Nicole Grieselhuber MD, PhD - Last Updated: February 19, 2025Nicole Grieselhuber, MD, PhD of The Ohio State University discusses a phase 1 study on SEA-CD70, a non-fucosylated monoclonal antibody targeting CD70 in high-risk MDS. The combination with azacitidine was well tolerated, with a 44% response rate and 16% of patients proceeding to stem cell transplant.
Advertisement
Advertisement
Related Posts
Investigators observed that overall treatment has improved but hospitalizations and other events indicate unaddressed need.
Andrew M. Evens, DO, MBA, MSc, shared practice-changing studies in Hodgkin lymphoma and what to expect in 2025.
Martin Dreyling, MD, discusses the TRIANGLE study and the shifting roles of autologous HSCT and chemotherapy in MCL.
Harboring high molecular risk mutations and a lower JAK2V617F VAF were independent adverse prognostic factors for survival.
The Myelofibrosis Symptom Assessment Form is the only instrument currently available for evaluating myelofibrosis symptoms.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.